Republicans urge end to mail-order abortion pill policy over health risks

Republicans urge Trump administration to end Biden-era mail-order abortion pill policy, citing health risks.
175 lawmakers urge FDA to halt mail-order abortion drugs

Republican Lawmakers Push for Termination of Mail-Order Abortion Pills Policy

FDA Building 21 stands behind the sign at the campus’s main entrance and houses the Center for Drug Evaluation and Research. The FDA campus is located in Silver Spring, Maryland. | Official FDA photo

A group of Republican lawmakers is urging the Trump administration to reverse a Biden-era policy that permits the distribution of abortion pills via mail, citing significant health concerns.

On Thursday, 175 Republican representatives signed a letter addressed to U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. and FDA Commissioner Marty Makary. The letter calls for a review of the reported negative effects of mifepristone, the first medication used in chemical abortions. Notably, only 44 House Republicans opted not to sign.

The legislators are advocating for the Trump administration to restore the requirement for in-person dispensing of mifepristone. Under the Biden administration, changes by the FDA allowed abortion pills to be mailed to patients without an in-person doctor’s visit, as reported in a previous article.

The lawmakers reference a study by the Ethics and Public Policy Center, which found that approximately 10.93% of women taking the abortion pill experience adverse effects such as sepsis, hemorrhaging, or infections. This study contributes to growing concerns regarding the safety of mifepristone.

Critics of the mail-order policy argue that it allows drugs to be distributed across state lines without physician oversight, potentially enabling individuals to administer the pills without the woman’s consent.

Republicans highlight that chemical abortions now account for two-thirds of all abortions in the U.S., attributing this to the “reckless” policies of the Biden FDA. They claim that these policies lead to increased profits for abortion providers at the expense of women’s health and unborn children.

FDA Commissioner Makary and Secretary Kennedy have both indicated plans to conduct a review of mifepristone, as indicated in prior commitments.

The discussion is further fueled by criticism faced by the Trump administration following FDA approval of a generic abortion drug. This move attracted backlash from pro-life advocates, as reported in a recent article.

Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, emphasized the dangers of women taking abortion drugs without medical supervision. She referenced a recent case in Ohio where a man allegedly forced abortion pills on his pregnant girlfriend, leading to severe consequences.

Dannenfelser stated, “Every day the FDA allows Joe Biden’s radical COVID-era abortion drug policy to stand, more unborn children die and more women end up in the [emergency room.]” Her comments reflect ongoing concerns about the safety and ethical implications of mail-order abortion pills.

For further information, Ryan Foley, reporter for The Christian Post, can be reached at ryan.foley@christianpost.com.

This article was originally written by www.christianpost.com

Author

Share:

More Posts

Send Us A Message

Subscribe